ABSTRACT
Hypoxia-inducible factor 2α (HIF-2α) plays a pivotal role in the balancing of oxygen request throughout the body. The protein is a transcription factor that modulates the expression of a wide array of genes and, in turn, controls several key processes including energy metabolism, erythropoiesis and angiogenesis. We describe here the identification of two cases of familial erythrocytosis associated with heterozygous HIF2A missense mutations, namely Ile533Val and Gly537Arg. Ile533Val is a novel mutation and represents the genetic HIF2A change nearest to Pro-531, the primary hydroxyl acceptor residue, so far identified. Gly537Arg missense mutation has been already described in familial erythrocytosis. However, our patient is the only described case of a de novo HIF2A mutation associated with congenital polycythemia development. Functional in vivo studies, based on exogenous expression of hybrid HIF-2α transcription factors, indicated that these genetic alterations lead to the stabilization of HIF-2α protein. All the identified polycythemic subjects with HIF2A mutations show serum erythropoietin in the normal range, independently of the hematocrit values and phlebotomy frequency. The erythroid precursors obtained from the peripheral blood of patients showed an altered phenotype, including an increased rate of growth and a modified expression of some HIF-2α target genes. These results suggest the novel proposal that polycythemia observed in subjects with HIF2A mutations might be also due to primary changes in hematopoietic cells and not only secondary to increased erythropoietin levels.
INTRODUCTION
Regulation of oxygen homeostasis is critical to survival. Accordingly, eukaryotes have developed molecular mechanism(s) for the maintenance of a proper oxygen tissue level. A major physiologic consequence of hypoxia is the enhanced renal synthesis of erythropoietin (EPO) and the increase of serum EPO. In turn, the cytokine stimulates red cell production restoring the oxygen supply to tissues. 1, 2 EPO is produced by kidney interstitial fibroblasts in close association with peritubular capillary and tubular epithelial cells. 3, 4 The cytokine is also synthesized in the perisinusoidal cells in the liver. 5 However, while liver synthesis predominates in the fetal and perinatal period, renal production is clearly predominant during adulthood. The hypoxia-dependent up-regulation of renal EPO production is almost exclusively due to the activation of EPO gene transcription. 3, 4 The protein is then rapidly modified and released in the serum. Erythroid precursors at specific differentiation stages express high level of EPO receptor (EPOR) whose engagement results in an increased red cell production. [6] [7] [8] Induction of EPO gene transcription by hypoxia has led to the discovery of the transcription factor hypoxia-inducible factor (HIF) and the molecular pathways that allow the modulation of HIF levels by oxygen levels. 9 HIF consists of two subunits, HIF-α and HIF-β, whose nuclear heterodimerization results in the active form. Only HIF-α, that exists in two isoforms HIF-1α and HIF-2α, levels are regulated by oxygen content. 10-13 Particularly, normoxia induced the ubiquitin-mediated degradation of HIF-α. Conversely, cellular HIF-α isoforms levels are increased by low O 2 partial pressure.
The ubiquitination of HIF-α requires a previous prolyl-4-hydroxylation that commits the transcription factor for the interaction with an E3 ubiquitin-protein ligase. 14-17
The E3 complex is formed by various proteins including: the von Hippel-Lindau protein (VHL), elongins B and C, cullin 2, and RBX1. 14-17 Three prolyl hydroxylases (PHD 1-3), identified in mammalian cells, use O 2 as a substrate to generate 4-hydroxyproline at specific prolyl residues of HIF-α. 18, 19 The primary site of hydroxylation of HIF-2α is Pro-531 that corresponds to proline 564 in HIF-1α. 20, 21 The hydroxyproline represents a specific degron that allows HIF-2α recognition by VHL. 22 Under normoxic conditions, PHDs (mainly PHD2) and VHL activities maintain the HIF-α (both HIF-1α and HIF-2α) content at almost undetectable levels. 23 Conversely, hypoxic conditions rapidly decrease HIF-α prolyl hydroxylation thus allowing the accumulation of the transcription factor. 23 In the nucleus, HIF-α associates with HIF-β forming an active complex endowed with a transcriptional activity. 24 HIF-α/HIF-β heterodimer binds to target consensus sequences in the regulatory regions of several hundreds of genes and activates their expression. [25] [26] [27] HIF target genes are involved in the control of a plethora of molecular processes including the regulation of cell growth and differentiation, the activation of apoptosis and the modulation of cell movement and migration. 25-27 Accordingly, several complex physiological and pathological events are regulated by HIF levels like hormone regulation, energy metabolism, angiogenic signaling, vasomotor regulation, matrix and barrier functions, transport and virus-related genes. 25- 27 Although still debated, a number of data suggest that HIF-1α/HIF-β and HIF-2α/HIF-β regulate different genes and modulate, in part, distinct processes. 28 Recent studies have identified congenital erythrocytosis-associated mutations in the genes that encode for VHL, PHD2 and HIF-2α. 29-41 Particularly, the genetic changes embrace homozygous or compound heterozygous mutations of VHL gene, heterozygous PHD2 gene changes, and heterozygous mutations of the HIF2A gene.
29-41
Specific HIF2A and PHD2 haplotypes have also been associated with adaptation to high altitudes in Tibetans, confirming the central role of the genes in hypoxic response. 42-44 Interestingly, no mutation of HIF1A has been reported so far. 35, 45 Mechanistically, PHD2 and VHL mutations lead to loss of function of the respective proteins, while the HIF2A mutations probably lead to a gain of function of HIF-2α. 29-41 A small number of subjects affected by inherited HIF2A mutations (Pro534Leu, Met535Val, Met535Ile, Met535Thr, Gly537Trp, Gly537Arg, Asp539Glu, Phe540Leu) in heterozygosity have been described. These patients show a dominant erythrocytosis and an increased or inappropriately normal EPO serum levels. 34- 41 In some cases, the patients present a history of thrombosis or pulmonary hypertension. 35 Increased serum EPO is supposed to be the cause of erythrocytosis in these patients. In addition to these patients, 3 cases of somatic gain-of-function HIF2A mutations (Ala530Thr, Ala530Val, Phe374Tyr) associated with paraganglioma and polycythemia as well as with increased serum EPO have been reported. [46] [47] [48] In the present report, we identify two HIF2A mutations associated with erythrocytosis and analyze the effect of the genetic change on the transcription factor stability and activity. One change is a de novo mutation, a condition that represents the first direct genetic proof that HIF2A mutations might be the cause of hereditary erythrocytosis.
We also describe, for the first time, the features of red cell progenitors prepared from the patients bearing HIF2A genetic changes.
Patients
We have analyzed a series of 75 patients with sporadic, apparently congenital or familial erythrocytosis. All patients gave informed written consent on entering the study, which had been approved by the Second University of Naples, Ethics
Committee, in accordance with the Declaration of Helsinki. of 0.53) with EPO level near to the low limit of normal range (6.1 mU/ml).
Mutation screening
Genomic DNA were collected at diagnosis from all patients and relatives.
Erythroid precursor cultures
Liquid cultures of peripheral erythroid precursors were prepared by employing peripheral blood CD34+ cells as a source of progenitors. 
In vitro prolyl 4-hydroxylation assays
Enzymatic activities of recombinant PHD1, PHD2 and PHD3 on HIF-2α peptide mutants were determined by an His6-and thioredoxin-tagged pVHL/elongin B/elongin C (VBC) binding assay essentially as described before. 49, 50
Luciferase assays
The experiments were performed essentially as reported in ref 49, 50. 
RESULTS

Clinical and genetic characterization of patients
Effect of HIF-2α mutations on protein metabolism
The detected mutations share two key features with previously described pathogenetic HIF2A changes. First, both the mutations occur in heterozygosity.
Second, they affect residues that follow closely the main and primary site of prolyl hydroxylation in HIF-2α (i.e. Pro-531). However, the occurrence of HIF-2α-dependent familial erythrocytosis with normal EPO serum level might cast some doubts on the effect of mutations on HIF-2α stability and, in turn, on the molecular mechanism(s) of the disease.
Previously reported in vitro experiments suggested that Gly537Arg mutation affects the interaction of HIF-2α peptides with PHD2 and VHL as well as its capability to act as hydroxyl acceptors. 39 Thus, we performed experiments to evaluate the ability of different PHDs (PHD1-3) to hydroxylate Pro-531 on peptides including Gly537Arg or Ile533Val changes . Therefore, wild-type ( Thus, the method allows the assessment of PHD activity on a putative substrate peptide by quantifying the binding to the hydroxylated peptide of the VBC complex (and not simply to VHL protein).
As shown in Fig. 4B , biotinylated peptides (from HIF-1α and HIF-2α) containing increasing proportions of synthetically generated hydroxyproline residue, demonstrate a direct proportionality between the absorbance at 405 nm and the percentage of peptide hydroxylation. Addition of recombinant active PHD1 to 3 to wild-type peptides also increased VBC binding (Fig. 4C) . Finally, since we preferred to use oxidation-insensitive peptides where methionine 535 is substituted by alanine, we confirmed that this change did not affect the efficiency of hydroxylation by the three PHDs (Fig. 4D) .
Next, we evaluated the hydroxylation of 5 different peptides, encompassing the region from 523 to 542, which carry the following changes: Gly537Arg, Ile533Val, Gly537Ala, Gly537Trp and Ala535Val (Fig. 5A) . We also tested a wild-type peptide (as a positive normal control) and the Pro531Ala (P531A) mutant peptide (as the negative control). In the absence of recombinant PHDs, no Pro-531 hydroxylation occurs (Fig. 5B) . In contrast, in the presence of all PHD isoforms, VBC binding to the wild-type peptide is approx. 8-10-fold higher than to the P531A mutant peptide (Fig. 5C) . None of the five HIF-2α mutations analyzed affected the efficiency of PHD-dependent hydroxylation, except the repeatedly observed diminished PHD3-dependent hydroxylation of the Gly537Arg mutant (Fig. 5C ). (Fig. 5D) . Interestingly, the fold increase was similar as the proline double mutation when one of the three indicated mutations was introduced into the ODD domain, suggesting that these mutations led to a comparable protein stabilization (Fig. 5D) .
To investigate whether
Following overexpression of PHD 1 to 3, a strong reduction of luciferase activity in the wild-type control sample was observed (Fig. 5D) . Conversely, no decrease of luciferase activity was observed in the samples transfected with ODD lacking the two pivotal prolines. In contrast to the normoxic basal conditions, overexpression of either of the three PHDs led to a partial inhibition of luciferase activity mediated by the three mutant fusion proteins, most likely due to a partial inhibition of their VHLmediated degradation (Fig. 5D) . Of note, diminished proline hydroxylation of Gly537Arg by PHD3 could not be confirmed by the transfection experiments.
Effect of HIF-2α mutations on erythroid precursor phenotype
As reported above, the serum EPO levels did not increase in the identified polycythemic patients with HIF2A mutations. Conversely, EPO concentrations frequently corresponded to the lower level of the interval range and, thus, might not explain the erythrocytosis in these patients.
Since HIF-2α might affect the expression of a significant number of genes modifying cell phenotypes, we wondered whether erythroid precursors of patients showed Previous experiments demonstrated that peripheral erythroid progenitors of congenital polycythemic subjects are hypersensitive to EPO by an as of yet unknown underlying mechanism. The feature is particularly evident at EPO concentration lower than 1U/ml. Thus, to investigate the phenotypical features of erythroid precursors of our patients, we characterized their in vitro proliferation. In these experiments, EPO was employed at a low concentration (0.1 U/ml) to identify a putative hyper-responsivity to the cytokine. As shown in Fig. 6B , erythroid precursors from our patients showed an increased growth rate when compared to a control as determined by direct cell counting.
concentrations were determined in the growth medium of the erythroid precursors after 7 days (i.e. from day 0 to day 7) and 14 days (i.e. from day 8 to day 14) of culture. As shown in Fig. 6C , protein data correlated with the mRNA data shown in 
DISCUSSION
In the present study a novel HIF2A mutation (Ile533Val) occurring in congenital erythrocytosis has been characterized. Moreover, a polycythemic subject, in which the presence of a de novo HIF2A genetic change (Gly537Arg) is associated to the development of the disease, was identified. The HIF2A-dependent erythrocytosic patients did not show serum EPO increase. The cytokine was, conversely, repeatedly found near the lower value of the physiological interval range independently of phlebotomy. These findings suggest that HIF2A mutations might induce erythrocytosis, at least in the described cases, by affecting processes independent of increased EPO production. Accordingly, we found that HIF2A genetic changes affect the phenotype of erythroid precursors.
The novel genetic HIF2A change identified, namely Ile533Val mutation, represents the hereditary alteration closest to Pro-531 reported so far. 33 Although the missense is clearly a conservative substitution, i.e. a bulky hydrophobic amino acid is substituted by another large hydrophobic residue, the change produces significant functional defects. Intriguingly, Ile-533 is conserved in HIF-2α proteins from mammalian species, human HIF-1α and HIF-3α, as well as HIF-2α proteins from chicken, frog, and zebrafish. The importance of this residue is further highlighted by X-ray crystallographic studies on the configuration of a HIF-1α peptide bound to VHL and the co-crystal structure of HIF-1α (556-574):PHD2. 51-53 These structures
show that Ile 566 in HIF-1α (that corresponds to Ile-533 of HIF-2α) is localized in one of two regions that are predicted to make essential contacts with VHL and PHD2
(residues 528-533 and residues 539-542).
Our study also describes the first identified case of a de novo HIF2A mutation associated with the development of congenital polycythemia. The genetic change reported, glycine 537 to arginine, occurs in 7 out of the 19 cases of HIF2A mutations (5 out of 12 families) associated with congenital polycythemia so far described (including ours). [35] [36] [37] As mentioned in the Introduction, a further change at Gly-537 (Gly537Trp) has been identified in 3 patients (1 family), allowing to consider Gly-537 as a hot spot in the HIF2A gene. 34 Following the identification of the erythrocytosis-associated Gly537Arg and
Ile533Val HIF2A gene mutations, we functionally characterized the two mutant proteins. Functional studies on the Gly537Arg HIF-2α mutant have been published previously, although employing distinct experimental approaches. A further observation of this study is that no increase of serum EPO was observed in the polycythemic patients identified here. 34-41 Similar data have been reported in other studies on HIF2A-dependent polycythemias although scarce attention has been paid to the finding. 37-44 So far 7 patients, including the case reported here, have been found to present Gly537Arg HIF2A mutation. Three patients belong to the same family. Two of them had a very high EPO (about 2000 mU/ml) while the third showed normal EPO levels (26 mU/ml). 37 Other 3 subjects (3 families) showed an EPO content from 60 mU/ml to >200 mU/ml. 36 Our patient has an EPO of about 6-18 mU/ml. Thus, there is no apparently interplay between a specific HIF2A change and EPO level. Two hypotheses might explain the absence of correlation between the genetic status and the cytokine level. One is the different genetic background of subjects and the other might be the age of patients (and their treatments including phlebotomies).
Since variation of serum EPO content might not explain the polycythemic phenotype of our patients, we hypothesized that erythrocytosis might be due (at least in part) to intrinsic alterations of erythroid precursors and/or other components of the hemopoietic niche. We found that peripheral erythroid precursors from the HIF2A-dependent polycythemic patients showed an increased rate of growth in vitro when compared to the normal counterpart.
An increased hypersensitivity to EPO has also been observed in the erythroid progenitors from congenital polycythemic patients due to the Chuvashian VHL (R200W) mutation. 29, 54 Recently, it has been suggested that this could be due to impaired degradation of phosphorylated JAK2 related to altered binding of VHL R200W with SOCS. 55 Moreover, a noticeable up-regulation of the expression of some HIF-2α target genes was also evidenced in these cells, confirming observations reported in other cell systems showing HIF-2α mutated protein.
34, 38, 39
Two different approaches confirmed the last finding, namely quantitative PCR and the direct evaluation of HIF-2α-regulated protein released by the erythroid precursors in the culture medium. Altogether, these data demonstrate, for the first time, that erythroid precursors from patients with congenital erythrocytosis due to HIF2A gainof-function mutations present a different phenotype with respect to the normal counterpart. This finding also suggests, as also indicated by recent data, 56 that HIF-2α is essential for excessive erythropoiesis in defects of the hypoxia sensing pathway.
In conclusion, our study identifies a novel HIF2A mutation responsible of hereditary erythrocytosis and reports the occurrence of a de novo HIF2A change associated to the development of the disease. Moreover, we suggest that the functional effects of the mutations should be evaluated mainly by in vivo experiments. Finally, we believe that the erythrocytosis due to HIF2A genetic changes is not simply a consequence of EPO increase but is probably due to more general effects on different cell phenotypes including the erythroid precursors cells.
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SUPPLEMENTARY METHODS
Patients
All patients had an elevated hematocrit (Hct), with normal leukocyte and platelets counts, and serum EPO level normal or inappropriately high for their Hct.
Materials
Human VEGF Quantikine ELISA Kits TFR were obtained by R&D Systems (Minneapolis, MN 55413, USA). sTfR Human ELISA (soluble Transferrin Receptor)
was from Biovendor (Brno, The Czech Republic). All the peptides employed were synthesized by GenScript Corporation (Scotch Plain, NJ 07076.0855, USA).
Mutation screening
All patients were screened for VHL, EPOR, PHD1, PHD2, PHD3, HIF1A, HIF2A gene mutations. 1
Erythroid precursor cultures
The details of preparation procedure, culture conditions and cell characterization are 
In vitro prolyl 4-hydroxylation assays
Briefly, biotinylated human wild-type or mutant HIF-1α-or HIF-2α-derived peptides (HIF-1α, amino acids 555-573; HIF-2α, amino acids 523-542) were bound to NeutrAvidin-coated 96-well plates (Thermo Scientific, Rockford, IL USA 61101).
Recombinant GST-PDH1, GST-PHD2 or GST-PHD3 enzymatic assays were carried out for 1 h at room temperature. Bound VBC complex was detected by rabbit antithioredoxin antibodies and secondary horseradish peroxidase-coupled anti-rabbit antibodies (Sigma) using the 3,3,5,5-tetramethylbenzidine substrate kit (Thermo Scientific). The peroxidase reaction was stopped by adding H 2 SO 4 , and absorbance was determined at 450 nm in a microplate reader. Inter-assay comparability was guaranteed by calibration of each experiment to an internal standard curve using hydroxyproline-containing peptides. 
